Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience.
The clinical experience of 1,723 patients treated with imipenem/cilastatin in worldwide clinical trials is reviewed. Dosages of imipenem administered parenterally with cilastatin varied with the severity of the infection and included 250 mg four times a day; 500 mg three or four times a day, and 1 g three of four times a day. Infections of all body systems except the central nervous system due to gram-positive or gram-negative aerobes and anaerobes as well as those due to mixed organisms were treated. Clinical efficacy was demonstrated in 92% of infections. The adverse clinical and laboratory experiences associated with imipenem/cilastatin were similar to those of other beta-lactam agents and included disturbances of gastrointestinal and central nervous system function, allergic reactions, and transient elevations of liver enzyme levels.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002490:Central Nervous System / Q000187:drug effects; D015377:Cilastatin; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000009:adverse effects; D004064:Digestive System / Q000187:drug effects; D004342:Drug Hypersensitivity; D004359:Drug Therapy, Combination; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D005260:Female; D006801:Humans; D015378:Imipenem; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D013845:Thienamycins / Q000008:administration & dosage* / Q000009:adverse effects; D014552:Urinary Tract Infections / Q000188:drug therapy
D003521:Cyclopropanes; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem